OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Makker on Synergy Between Lenvatinib and Pembrolizumab in Endometrial Cancer

August 10th 2018

Vicky Makker, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the synergy between lenvatinib and pembrolizumab in the treatment of patients with endometrial cancer.

Dr. O'Malley on Folate-Receptor Alpha as a Biomarker in Ovarian Cancer

August 10th 2018

David O'Malley, MD, professor, Department of Obstetrics and Gynecology, The Ohio State University Comprehensive Cancer Center, discusses folate-receptor alpha as a biomarker in ovarian cancer.

Dr. Camidge on Biomarker Combinations in NSCLC

August 10th 2018

David Ross Camidge, MD, PhD, professor, Division of Medical Oncology, Joyce Zeff Chair in Lung Cancer Research, School of Medicine, Division of Medical Oncology, University of Colorado, discusses biomarker combinations in non–small cell lung cancer (NSCLC).

Dr. Novik on CDK4/6 Inhibitor Combinations in Breast Cancer

August 10th 2018

Yelena Novik, MD, associate professor, NYU Langone’s Perlmutter Cancer Center, discusses CDK4/6 inhibitor combinations in breast cancer.

Dr. Herbst on Key Immunotherapy Findings in NSCLC

August 10th 2018

Roy S. Herbst, MD, PhD, professor of Medicine, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses key immunotherapy findings in non–small cell lung cancer, presented at the 2018 ASCO Annual Meeting.

Dr. Kalinsky Discusses Biosimilars in Breast Cancer

August 10th 2018

Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical School, discusses the promise of biosimilars in breast cancer.

Dr. Pemmaraju on the Trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasms

August 10th 2018

Naveen Pemmaraju, MD, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the trial of SL-401 in blastic plasmacytoid dendritic cell neoplasms.

Dr. Hurvitz on How to Navigate HER2-Targeted Therapy in Breast Cancer

August 10th 2018

Sara A. Hurvitz, MD, director of the Breast Oncology Program at the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, advises how to navigate therapy for patients with HER2-positive breast cancer.

Dr. Menter on Neoadjuvant Immunotherapy in Early-Stage NSCLC

August 10th 2018

Alexander R. Menter, MD, oncologist, Kaiser Permanente, discusses the use of neoadjuvant immunotherapy in patients with early-stage non–small cell lung cancer (NSCLC).

Dr. Arun Considers Biosimilars in the Context of Global Cancer Care

August 10th 2018

Banu Arun, MD, professor in the Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses biosimilars in the context of global cancer care.

Dr. Aisner on the Limitations of Molecular Profiling

August 10th 2018

Dara L. Aisner, MD, PhD, associate professor in the department of Pathology at the University of Colorado School of Medicine, discusses the limitations of molecular profiling.

Dr. Gupta on Genomic Characterization of MIBC Histology to Predict Response

August 9th 2018

Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses genomic characterization of muscle invasive bladder cancer histology to predict therapy response.

Dr. Hussain on Potential of Enzalutamide in Prostate Cancer

August 9th 2018

Maha H. Hussain, MD, FACP, Genevieve Teuton Professor of Medicine, deputy director, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses the potential of enzalutamide in prostate cancer.

Dr. Tolaney on Selecting Patients for CDK4/6 Inhibitors in Breast Cancer

August 9th 2018

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses selecting patients with estrogen receptor (ER)-positive breast cancer for treatment with CDK4/6 inhibitors.

Dr. Chi Discusses Tazemetostat Trial in INI1-Negative Pediatric Tumors

August 9th 2018

Susan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses a trial of tazemetostat in pediatric patients with INI1-negative tumors.

Dr. Shah Discusses the BRIGHTER Study in Gastric Cancer

August 9th 2018

Manish A. Shah, MD, director of gastrointestinal oncology and chief of Solid Tumor Service at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the BRIGHTER study in patients with gastric and gastroesophageal junction (GEJ) adenocarcinoma.

Dr. Eyre on Results of Venetoclax in Relapsed/Refractory MCL

August 9th 2018

Toby Eyre, MBChB, MRCP, consultant hematologist at Oxford University Hospitals NHS Trust, discusses the results of single-agent venetoclax (Venclexta) in patients with relapsed/refractory mantle cell lymphoma.

Dr. Yezefski on Differences in CRC Care Costs Between the US and Canada

August 9th 2018

Todd A. Yezefski, MD, senior fellow, Fred Hutchinson Cancer Research Center, University of Washington, discusses the differences between colorectal cancer care costs in the Unites States and Canada.

Dr. Bosse on Challenges With Immunotherapy in Pediatric Cancers

August 9th 2018

Kristopher Bosse, MD, attending physician, Division of Oncology, The Children's Hospital of Philadelphia, discusses challenges with immunotherapy in pediatric cancers.

Dr. Bota on Marizomib in Patients with Glioma

August 8th 2018

Daniela Bota, MD, PhD, medical director, Neuro-Oncology Program, associate professor, Neurology School of Medicine, UC Irvine Health, discusses marizomib for the treatment of patients with glioma.